HUGE Impressive Rise since it touched 0.0082 on Aug 20th

VPRO - 0.0195 - Another 11% steady rise VPRO -
Just keeping you guys in loop when it happens, not after it has happened - Been alerting since 0.01

VPRO - 0.0195 - Another 11% steady rise VPRO - I will not pump - Just keeping you guys in loop when it happens, not after it has happened - Been alerting since 0.01

I had Alerted VPRO below 0.01 - Now 0.017 No hoopla

I had Alerted VPRO below 0.01 Now 0.017

Watch out for VPRO Up 28% at 0.014

VPRO at 0.014 Up 28% on 3.6M volume

High of 0.014 so far

VPRO - 0.02 from 0.0085 on Fri !

VPRO Fri 0.0085 to 0.02 today !

VPRO 0.0085 --> 0.012 --> 0.016 Last two days good action

VPRO UP 2 days - 0.0085 --> 0.012 --> 0.016 close today !

0.016 - Hope it closes at that high !

NOTICE OF VOLUNTARY RESIGNATION
Effective immediately, I hereby resign my positions as President and Chief Executive Officer of VIROPRO, INC., its affiliates and
subsidiaries. In addition, effective immediately, I hereby resign my position as a member of the Board of Directors of VIROPRO, INC., its
affiliates and subsidiaries.


Dr. Rajiv Datar

Is this true in the filings ?

Game-Changers: 5 Mobile App Search Leaders To Watch

http://seekingalpha.com/article/687351-game-changers-5-mobile-app-search-leaders-to-watch?source=google_news

VRNG - Altucher latest article at 5 AM
Google Vs. Vringo: Vringo Delivers A Knockout In Round One

http://seekingalpha.com/article/668211-google-vs-vringo-vringo-delivers-a-knockout-in-round-one

Altucher latest article at 5 AM
Google Vs. Vringo: Vringo Delivers A Knockout In Round One

http://seekingalpha.com/article/668211-google-vs-vringo-vringo-delivers-a-knockout-in-round-one

Another news on SPPI
In a 13G filing on Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), investment fund Tang Capital Management disclosed a 7.72%, or 4,577,895 share, stake in the company. This is up 157.49% from the 1,777,895 shares held at the end of the latest quarter ending March 31, 2012.

Today's news : From local Start Ledger (NJ) paper on BIOSIMILARS today -
http://www.nj.com/business/index.ssf/2012/02/regulators_set_a_course_for_dr.html

Thank U for all your research ..
Dave Chappelle and Chris rock - rock My favorite comedians!
U rock!

lol It was in 200s then Now 370 !
So Conclusion : Not a Pig - Just a smart co with long lines....

Everyday New Highs - $370 today

VPRO/SPPI have been steady lately
In the big space I like CMG Always increasing daily to new highs

+1 or should I say +69 (69 is my favorite number !)

I too want to thank U - U have more News than VPRO

Aiming for 0.06 and beyond in next run !

VPRO's partner SPPI makes new Highs every day

For teh last month or so - Todat at 15.22 a few days back it made 15.089 Keeps breaking prev highs every few days or day !

Nice sign for VPRO

Some people I know who have been in SPPI are beginning to look into VPRO after a 150% gain in that !

SPPI making new highs everyday - Hope VPRO follows soon

Why not 0.000026 while you are at it ! Anyway U NYSE wannabe !

Yes FRHV has awesome Chart I agree

FRHV go on break that 0.015 and reach high since Apr 2011

0.014 FRHV awesome 6 month high

Nobody does anything without a reason - I am sure his real reasons are different. Otherwise why would anyone who treats Pinkies like NYSE stock analysis be here ? He has some other reason - which no one will know . I have never seen a guy hanging around boards just for fun and bashing stocks they own ! At least they wait till they sell it !

U have still not sold your shares when U had chance at above 0.05 with huge volume ? lol I thought you are interested in more stable NYSE stocks lol

More profiles of her

http://womensbiz.us/archives/profiles0804.asp

http://www.executiveaction.com/tsai

MIT guy and now Wall street - and all losers like kingfisher disappeared - Never trust losers !

VPRO mentioned here ! Not sure good or bad !

http://www.businessweekly.co.uk/blog/cambridge-today-tony-quested/12660-overpaid-over-sexed-and-over-here

VPRO/SPPI compared with Genentech

good Article

http://www.institutionalinvestor.com/Popups/PrintArticle.aspx?ArticleID=2888728

“What we are offering is a proven manufacturing platform that can help drugmakers improve their manufacturing yields,” says Rajiv Datar, CEO of Viropro, an Irvine, California, company that offers contractual research and manufacturing services to biopharmaceuticals companies. Almost a vanguard company, Viropro can help many pharmaceuticals companies test the biosimilars market with far less risk and cost than they could on their own. It has signed up some major pharmaceuticals manufacturers, such as Spectrum Pharmaceuticals, to develop a biosimilar to Genentech’s Rituximab, which is used to treat non-Hodgkin lymphoma. In 2009, Rituximab had sales of $5.6 billion worldwide.

“What we are offering is a proven manufacturing platform that can help drugmakers improve their manufacturing yields,” says Rajiv Datar, CEO of Viropro, an Irvine, California, company that offers contractual research and manufacturing services to biopharmaceuticals companies. Almost a vanguard company, Viropro can help many pharmaceuticals companies test the biosimilars market with far less risk and cost than they could on their own. It has signed up some major pharmaceuticals manufacturers, such as Spectrum Pharmaceuticals, to develop a biosimilar to Genentech’s Rituximab, which is used to treat non-Hodgkin lymphoma. In 2009, Rituximab had sales of $5.6 billion worldwide.

Yep SPPI/VPRO will do well - You cannot go wrong in the Genentech biosimilar arena - The best firm to work for till Google/Apple stated raining their parade in California!

Good article

Small companies such as Prolor Biotech and Viropro are discovering that part of their capital-raising campaign has to include efforts to educate potential investors and stakeholders about what biosimilars are, how they will affect the whole process of health care and how a more transparent regulatory environment would be helpful. “It’s all about clear rules and certainty,” says Sharon di Stefano, a health care analyst with Fordham Financial Management in New York. “Once you know what the rules are, investors will follow.”




What we are offering is a proven manufacturing platform that can help drugmakers improve their manufacturing yields,” says Rajiv Datar, CEO of Viropro, an Irvine, California, company that offers contractual research and manufacturing services to biopharmaceuticals companies. Almost a vanguard company, Viropro can help many pharmaceuticals companies test the biosimilars market with far less risk and cost than they could on their own. It has signed up some major pharmaceuticals manufacturers, such as Spectrum Pharmaceuticals, to develop a biosimilar to Genentech’s Rituximab, which is used to treat non-Hodgkin lymphoma. In 2009, Rituximab had sales of $5.6 billion worldwide.

If the uncertainty clears, Viropro could be a big winner as it lines up manufacturing orders from a slew of drugmakers that want to test the biosimilars market.